US FDA declines to approve Replimune's drug for advanced skin cancer
10/04/2026 16:22
April 10 (Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Replimune's REPL.O drug for advanced skin cancer, the regulator said. (Reporting by Padmanabhan Ananthan & Sruthi Narasimha Chari in Bengaluru) ((Padmanabhan.Ananthan@thomsonreuters.com))
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly